Alpha Cognition (ACOG) and Its Rivals Financial Survey

Alpha Cognition (NASDAQ:ACOG) is one of 300 public companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its peers? We will compare Alpha Cognition to similar businesses based on the strength of its analyst recommendations, dividends, earnings, profitability, institutional ownership, valuation and risk.

Volatility & Risk

Alpha Cognition has a beta of 2.5, suggesting that its share price is 150% more volatile than the S&P 500. Comparatively, Alpha Cognition’s peers have a beta of -3.86, suggesting that their average share price is 486% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings for Alpha Cognition and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Cognition	0	0	1	0	3.00
Alpha Cognition Competitors	1921	5376	13914	295	2.59

Alpha Cognition presently has a consensus price target of $20.00, indicating a potential upside of 263.64%. As a group, “Biological products, except diagnostic” companies have a potential upside of 101.68%. Given Alpha Cognition’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Alpha Cognition is more favorable than its peers.

Valuation & Earnings

This table compares Alpha Cognition and its peers revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Alpha Cognition	N/A	-$13.77 million	-2.15
Alpha Cognition Competitors	$574.41 million	-$70.96 million	0.06

Alpha Cognition’s peers have higher revenue, but lower earnings than Alpha Cognition. Alpha Cognition is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Alpha Cognition and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alpha Cognition	N/A	N/A	-344.17%
Alpha Cognition Competitors	-2,185.76%	-161.46%	-40.62%

Insider and Institutional Ownership

50.4% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 31.5% of Alpha Cognition shares are owned by company insiders. Comparatively, 15.7% of shares of all “Biological products, except diagnostic” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Alpha Cognition beats its peers on 8 of the 13 factors compared.

Alpha Cognition Company Profile

Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.